Skip to main content

Market Overview

3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley

3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley

The bullish case for Nevro Corp (NYSE: NVRO) — a medical device company that focuses on the treatment of chronic pain — no longer applies for three reasons, according to Morgan Stanley.

The Analyst

Morgan Stanley's David Lewis downgraded Nevro from Overweight to Equal-weight with a price target lowered from $94 to $88.

The Thesis

The bullish case for Nevro's stock was based on the following expectations, Lewis said in a Monday downgrade note:

All three catalysts now hold risk, Lewis said.

Nevro's commercial message of boasting clinically superior therapies isn't resonating as much as expected, while competing platforms like Abbott Laboratories (NYSE: ABT) Burst and Medtronic PLC (NYSE: MDT)'s Intellis have gained market traction, the analyst said. 

Expectations for expansion into new markets not only hasn't occurred, but Nevro is stuck in a "near-term catalyst void," Lewis said, giving the example of the company's diabetic neuropathy and non-surgical back pipelines. After timeline delays, the candidates are slated to begin enrollment in mid-2019, the analyst said.  

The superiority of Nevro's Senza could face challenges from Saluda's Evoke system in January 2019 or beforehand, Lewis said. The Saluda platform can be programmed to automatically adjust stimulation levels to a patient's preferred level and could be statistically superior to traditional SCS treatments, negatively affecting Nevro's commercial message, he said. 

Price Action

Shares of Nevro were sliding 9.44 percent at the time of publication Monday. 

Related Links:

Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report

Nevro Has A Multi-Billion Dollar Opportunity

Photo courtesy of Nevro Corp. 

Latest Ratings for NVRO

Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Piper SandlerInitiates Coverage OnOverweight
Jan 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for NVRO
View the Latest Analyst Ratings


Related Articles (NVRO)

View Comments and Join the Discussion!

Posted-In: chronic pain David LewisAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at